Photocure divests Metvix to Galderma for EUR 51 million
02-Oct-2009 -
Photocure ASA has entered into agreements with Galderma S.A., under which Galderma has purchased global rights, assets, and liabilities related to Metvix and Metvixia, as well as the exclusive right to develop new dermatology products based on Photocure's patented substance, MAL. Photocure ...
dermatology
license agreements
photo-dynamic therapies
+1